News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Dicerna Reports First Quarter 2016 Financial and Operational Results
May 10, 2016
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the first quarter ended March 31, 2016.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Phase 2
Earnings
Dicerna Pharmaceuticals
MORE ON THIS TOPIC
Cardiovascular disease
BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival
May 12, 2026
·
2 min read
·
Tristan Manalac
Earnings
Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls
May 11, 2026
·
2 min read
·
Nick Paul Taylor
Manufacturing
Lilly invests $4.5B in Indiana manufacturing, opens doors of 1st genetic medicine site
May 8, 2026
·
1 min read
·
Gabrielle Masson
Earnings
Gilead sets blockbuster bar for Yeztugo’s first full year on the market
May 8, 2026
·
2 min read
·
Tristan Manalac
